Medical Devices

Find premium medical devices research reports. Purchase and download high quality report analysis, industry reports, medical device technology reports, company research reports, and much more

DocStore Search:
Per Page: 152550
  • 2ergo Group plc (RGO) - Financial and Strategic SWOT Analysis Review
    2ergo Group plc (RGO) - Financial and Strategic SWOT Analysis Review

    $125.00

    $125.00

    From:GlobalData

    Document Overview:
    2ergo Group plc (2ergo) is an international mobile business and marketing solutions company. The company provides innovative proprietary mobile technologies and professional services to support organizations to develop and execute their mobile strategy. It provides applications, and develops telecommunication software for mobile marketing, mobile customer relationship management, and mobile entertainment and media. Its product portfolio comprises an innovative suite of mobile publishing, messaging, content management, handset applications, mobile payment and connectivity solutions for delivering a multi-dimensional approach for mobile marketing and mobile customer communications.
    View Document
  • 32Red Plc (TTR) - Financial and Strategic SWOT Analysis Review
    32Red Plc (TTR) - Financial and Strategic SWOT Analysis Review

    $125.00

    $125.00

    From:GlobalData

    Document Overview:
    32Red Plc (32Red) is one of the leading online gaming providers in the UK. It offers interactive licensed betting and gaming operations over the internet. The company operates through the reportable segments, namely, Casino, Poker and Bingo. 32Red offers its users with more than 350 casino games, including poker, bingo, and roulette. These games are fully licensed and regulated by the Government of Gibraltar. The company’s brands include 32Red Online Casino, Dash Casino, Nedplay Casino, Golden Lounge Casino, 32Red Poker, 32Red Bingo, 32Red Mobile, 32Red Bet, 32Red Rummy and 32Red Financials. The company provides quality games offered by MicroGaming. 32Red is headquarted at Gibraltor
    View Document
  • 3i Group plc (III) - Medical Equipment - Investment Profile
    3i Group plc (III) - Medical Equipment - Investment Profile

    $250.00

    $250.00

    From:GlobalData

    Document Overview:
    3i Group plc (3i Group) is a UK-based global mid-market private equity and venture capital group. It focuses on private equity, infrastructure and debt management. 3i Group, along with its subsidiaries, manages various funds of institutions and other investors to make equity and equity-related investments, especially in unquoted businesses in Europe and Asia. It caters to the business and financial services, consumer, industrials and energy, health care, technology, media and telecoms sectors. The portfolio of the group include Foster + Partners, Eco US Holdings Inc (HILITE), Mold-Masters Luxembourg Holdings, ACR Capital Holdings Pte Limited, Peer Holdings BV (Action) and Mayborn Group Limited. It operates across the Europe, Asia and the US. 3i Group is headquartered in London, the UK. The strategic intent of the group is to grow in its area of expertise. In line with the strategy, the group through its subsidiary 3i Debt Management Ltd, acquired Mizuho Investment Management (UK) Limited. Post acquisition, the group formed a new businesses line, Debt management, merging the debt management activities of its subsidiary 3i Debt Management Ltd with MIM. The acquisition could enhance its capabilities in the debt fund management market and build upon the group's existing Private Equity and Infrastructure businesses. GlobalData’s Private Equity/Venture Capital firm - 3i Group plc (III) - Medical Equipment - Investment Profile report provides an overview of the firm’s operations and investments in the Medical Devices sector. The report incorporates a brief account of the firm’s Medical Devices investments for the last five years by segment and type. The report also includes information on major companies financed by the firm comprising their business description, key products and services, major competitors and key employees. Scope - Comprehensive analysis of investments made by the firm in the last five years - Analysis of deals by segment and investment typ
    View Document
  • 3M Company (MMM) - Medical Equipment - Deals and Alliances Profile
    3M Company (MMM) - Medical Equipment - Deals and Alliances Profile

    $250.00

    $250.00

    From:GlobalData

    Document Overview:
    3M Company (3M) is a diversified technology company. It specializes in the development, manufacture and marketing of wide range of innovative products and services catering diverse sectors. The company develops technology platforms, including adhesives, abrasives, light management, microreplication, nonwoven materials, nanotechnology, and surface modification. In addition, the company formed a renewable-energy division in order to tap the growing solar and wind energy market. The renewable energy division is further classified into two business units namely, Energy Generation and Energy Management. The operations of the company are spanned across various countries and its products are sold in countries across North and South America; Europe Middle East and Africa; and Asia Pacific. 3M is headquartered in Minnesota, the US. The company’s strategic aim focuses on expanding its operations globally through means of acquisitions. With an intent to enhance its offerings in the ceramics division, acquired Ceradyne, Inc. which will enable new technologies and innovation for the uniquely tailored materials which requires advanced ceramics. 3M Company (MMM) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research. Scope - Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture
    View Document
  • 3M Health Care Ltd. - Medical Equipment - Deals and Alliances Profile
    3M Health Care Ltd. - Medical Equipment - Deals and Alliances Profile

    $250.00

    $250.00

    From:GlobalData

    Document Overview:
    3M Health Care Ltd. (3M Health Care), a business segment of 3M Company, offers medical and oral care products, drug delivery and health information systems. Its products and services include skin health and infection prevention products, inhalation and transdermal drug delivery systems, dental and orthodontic products, health information systems, medical and surgical supplies, and food safety products. The company offers these products to various markets including medical clinics and hospitals, pharmaceuticals, dental and orthodontic practitioners, health information systems, and food manufacturing and testing. It has a presence in more than 200 markets around the world. 3M Health Care is headquartered in Leicestershire, the UK. 3M Health Care Ltd. - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research. Scope - Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table
    View Document
  • 5AM Ventures - Medical Equipment - Investment Profile
    5AM Ventures - Medical Equipment - Investment Profile

    $250.00

    $250.00

    From:GlobalData

    Document Overview:
    5am Ventures (5am Ventures) principally engages in operating as a venture capital firm, focusing on early-stage investments and spinouts. The company aims at investing in life science companies with a focus on drug development, medical technologies and product discovery. In drug development, the company focuses on companies in therapeutic areas such as diabetes, oncology, metabolic diseases, and anti-infectives. In medical technologies, the firm focuses on companies in areas such as diagnostics, materials science, drug delivery, and imaging agents. 5am Ventures seeks to take a board seat in its portfolio companies. The company is headquartered at Menlo Park, California, USA. In June 2013, AstraZeneca PLC, entered into an agreement to acquire Pearl Therapeutics Inc., for a purchase consideration approximately $1150m. In December 2012, the portfolio company of 5am Ventures, Incline Therapeutics, Inc., entered into an agreement with The Medicines Company (MDCO), under which the later will acquire the former. MDCO has agreed to pay $185m upfront and make additional payment if regulatory milestones are met. GlobalData’s Private Equity/Venture Capital firm - 5AM Ventures - Medical Equipment - Investment Profile report provides an overview of the firm’s operations and investments in the Medical Devices sector. The report incorporates a brief account of the firm’s Medical Devices investments for the last five years by segment and type. The report also includes information on major companies financed by the firm comprising their business description, key products and services, major competitors and key employees. Scope - Comprehensive analysis of investments made by the firm in the last five years - Analysis of deals by segment and investment type - Summary of private equity/venture capital trends in the industry for the last six months - Information on major companies financed by the firm - Detailed information about deals, including the stage of investment
    View Document
  • 8sens.biognostic GmbH  - Product Pipeline Analysis
    8sens.biognostic GmbH - Product Pipeline Analysis

    $750.00

    $750.00

    From:GlobalData

    Document Overview:
    8sens.biognostic GmbH - Product Pipeline Analysis Summary This report is a source for data, analysis and actionable intelligence on the 8sens.biognostic GmbH portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date. Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. Scope - Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments. - Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase. - Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date. - Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application. - Data on relevant clinical trials and product patent details, wherever applicable. - Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility. Reason
    View Document
  • A&G Pharmaceutical, Inc.  - Product Pipeline Analysis
    A&G Pharmaceutical, Inc. - Product Pipeline Analysis

    $750.00

    $750.00

    From:GlobalData

    Document Overview:
    A&G Pharmaceutical, Inc. - Product Pipeline Analysis Summary This report is a source for data, analysis and actionable intelligence on the A&G Pharmaceutical, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date. Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. Scope - Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments. - Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase. - Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date. - Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application. - Data on relevant clinical trials and product patent details, wherever applicable. - Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.
    View Document
  • A. Menarini Diagnostics S.r.l. - Medical Equipment - Deals and Alliances Profile
    A. Menarini Diagnostics S.r.l. - Medical Equipment - Deals and Alliances Profile

    $250.00

    $250.00

    From:GlobalData

    Document Overview:
    A. Menarini Diagnostics S.r.l. (Menarini Diagnostics) is a medical diagnostic company. The company offers healthcare professional cutting edge, hi-tech solutions for diagnostics needs. Its products include autoimmunity, continuous glucose monitoring system, haemoglobin analyser, home glucose testing, hospital monitoring systems, cell pathology, point of care testing, urinalysis, urine sediment, and wet chemistry. Menarini Diagnostics offers glucose testing products such as glucocard mx, glucocard g meter, glucocard x-meter, glucofix miò plus, glucofix miò, glucofix id, glucomen visio, glucomen LX plus, glucomen LX, glucomen gm, securject pro, glucoject dual s, glucolog software, glucolog lite, glucolog mobile, and glucolog B.T. device. Menarini Diagnostics is headquartered in Firenze, Italy.
    View Document
  • Aachen Resonance GmbH  - Product Pipeline Analysis
    Aachen Resonance GmbH - Product Pipeline Analysis

    $750.00

    $750.00

    From:GlobalData

    Document Overview:
    Aachen Resonance GmbH - Product Pipeline Analysis Summary This report is a source for data, analysis and actionable intelligence on the Aachen Resonance GmbH portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date. Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. Scope - Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments. - Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase. - Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date. - Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application. - Data on relevant clinical trials and product patent details, wherever applicable. - Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility. Reason
    View Document
  • AAIPharma Inc. - Strategic SWOT Analysis Review
    AAIPharma Inc. - Strategic SWOT Analysis Review

    $125.00

    $125.00

    From:GlobalData

    Document Overview:
    AAIPharma Inc. - Strategic SWOT Analysis Review Summary AAIPharma Inc. (AAIPharma) is a privately held drug development company that is engaged in providing services to pharmaceutical, biotechnology and medical device companies. It provides a wide range of services from drug discovery to registering new drug product candidates. The services include analysis, testing, packing, and marketing new products. AAIPharma also provides services for infrastructure and clinical data management. It has many facilities in Europe and the U.S. In April 2009, the company entered into a strategic alliance with Emisphere Technologies, Inc. to expand the application of Eligen Technology and drug development services. GlobalData’s AAIPharma Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better. Scope - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – GlobalData’s summarization of the company’s business strategy. - SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. - Company history – Progression of key events associated with the company. - Major products and services – A list of major products, services and brands of the company. - Key competitors – A list of key competitors to the company. - Key employees – A list of the key executives of the company. - Executive biographies – A brief summary of the executives’ employment history. - Key operational heads – A list of personnel heading key departments/functions. - Important
    View Document
  • aap Implantate AG (AAQ)  - Product Pipeline Analysis
    aap Implantate AG (AAQ) - Product Pipeline Analysis

    $750.00

    $750.00

    From:GlobalData

    Document Overview:
    aap Implantate AG (AAQ) - Product Pipeline Analysis Summary This report is a source for data, analysis and actionable intelligence on the aap Implantate AG portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date. Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. Scope - Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments. - Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase. - Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date. - Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application. - Data on relevant clinical trials and product patent details, wherever applicable. - Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility. Reasons
    View Document
  • Aastrom Biosciences, Inc. (ASTM) - Financial and Strategic SWOT Analysis Review
    Aastrom Biosciences, Inc. (ASTM) - Financial and Strategic SWOT Analysis Review

    $125.00

    $125.00

    From:GlobalData

    Document Overview:
    Aastrom Biosciences (Aastrom) is a development stage regenerative medicine company, which is involved in autologous cell products for use in regenerative medicine. The company’s principal business is to develop innovative cell therapies based products for use in multiple therapeutic areas like, cardiac and vascular. The company’s preclinical and clinical product development programs investigate the ability of patient-derived bone marrow stem and early progenitor cell populations to aid in regeneration of body tissues. The company aims to continually develop and add new high-quality products to its wide range of product catalogue, as well as increase validation of its current products with a stringent focus on data collection and presentation. Aastrom is headquartered in Michigan, the US.
    View Document
  • Aastrom Biosciences, Inc. (ASTM) - Medical Equipment - Deals and Alliances Profile
    Aastrom Biosciences, Inc. (ASTM) - Medical Equipment - Deals and Alliances Profile

    $250.00

    $250.00

    From:GlobalData

    Document Overview:
    Aastrom Biosciences, Inc. (Aastrom) is a development stage regenerative medicine company. It undertakes the design and development of autologous cell products for use in regenerative medicine. The company develops innovative cell therapies based products for use in multiple therapeutic areas like, cardiac and vascular. The company’s preclinical and clinical product development programs investigate the ability of patient-derived bone marrow stem and early progenitor cell populations to aid in regeneration of body tissues. Aastrom is headquartered in Michigan, the US. The company aims to continually develop and add new products to its wide range of product catalogue, as well as increase validation of its current products with a stringent focus on data collection and presentation. Aastrom Biosciences, Inc. (ASTM) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research. Scope - Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitio
    View Document
  • Abacus Property Group (ABP) - Financial and Strategic SWOT Analysis Review
    Abacus Property Group (ABP) - Financial and Strategic SWOT Analysis Review

    $125.00

    $125.00

    From:GlobalData

    Document Overview:
    Abacus Property Group (APG) is a diversified property group specialized in investing in core plus property opportunities. APG provides real estate and property financial services which include specialized property investment, funds management and property financing. In addition, the group offers mortgage lending and related property financing solutions. It holds a portfolio of retail, commercial and industrial properties and rental income coming from these properties are the biggest source of company's revenue. The activities of the company are classified into four segments, namely, Property, Funds Management, Property Finance and Storage.
    View Document
Per Page: 152550